Exploring the anticancer potential of Jerantinine A from Tabernaemontana coronaria against prostate, breast, and ovarian cancers: a computational approach

Poornima Kannappan; Meenakshi Kaniyur Chandrasekaran; Manikandan Vani Raju; Shankari Gopalakrishnan; Prabhu Dhamodharan; Rathi Muthaiyan Ahalliya; Chella Perumal Palanisamy; Balaji Raju; Gopalakrishnan Velliyur Kanniappan

doi:10.1515/jcim-2024-0443

Article

Exploring the anticancer potential of Jerantinine A from Tabernaemontana coronaria against prostate, breast, and ovarian cancers: a computational approach

Poornima Kannappan , Meenakshi Kaniyur Chandrasekaran , Manikandan Vani Raju , Shankari Gopalakrishnan , Prabhu Dhamodharan , Rathi Muthaiyan Ahalliya , Chella Perumal Palanisamy , Balaji Raju and Gopalakrishnan Velliyur Kanniappan

Published/Copyright: March 28, 2025

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Complementary and Integrative Medicine Volume 22 Issue 2

Abstract

Objectives

Cancer remains a significant global health challenge, with prostate, breast, and ovarian cancers ranking among the leading causes of morbidity and mortality. Natural products, particularly those derived from medicinal plants, have gained attention for their potential in alternative cancer therapies. The main objective of the study was an isolation and characterization of Jerantinine A, a bioactive alkaloid from Tabernaemontana coronaria, and its interactions with key protein targets involved in cancer progression.

Methods

Jerantinine A was isolated through column chromatography and characterized using spectroscopic techniques, including UV-visible spectroscopy, FTIR, and NMR. Molecular docking studies were performed to assess its binding affinities with six critical protein targets: PTEN and androgen receptor for prostate cancer, CXCR4 and HER2 for ovarian cancer, and CDK1 and NEK2 for breast cancer.

Results

Molecular docking analyses revealed that Jerantinine A exhibits strong binding affinities with all six protein targets, suggesting its potential to inhibit cancer cell proliferation by interfering with key signaling pathways.

Conclusions

These findings underscore the therapeutic potential of T. coronaria, particularly through Jerantinine A, as a promising candidate for cancer treatment. By targeting pivotal proteins associated with prostate, breast, and ovarian cancers, Jerantinine A offers a foundation for further research and development as a novel anti-cancer agent.

Keywords: Tabernaemontana coronaria ; Jerantinine A; molecular docking; prostate cancer; breast cancer; ovarian cancer

Corresponding author Dr. Gopalakrishnan Velliyur Kanniappan, Professor, Department of Physiology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai, 602105, Tamil Nadu, India, E-mail: vkgopalakrishnan@gmail.com

Acknowledgments

We, the authors are thankful to Karpagam Academy of Higher Education, Coimbatore for Laboratory facilities to completed the research work. We would also express our sincere thanks to SAIF, Cochin University of Science and Technology, Cochin, India for NMR analysis.

Research ethics: Not applicable.
Informed consent: Not applicable.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Use of Large Language Models, AI and Machine Learning Tools: None declared.
Conflict of interest: Authors state no conflict of interest.
Research funding: None declared.
Data availability: Not applicable.

References

1. Bray, F, Laversanne, M, Sung, H, Ferlay, J, Siegel, RL, Soerjomataram, I, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–63. https://doi.org/10.3322/caac.21834.Search in Google Scholar PubMed

2. Huang, J, Chan, WC, Ngai, CH, Lok, V, Zhang, L, Lucero-Prisno, DE, et al.. On behalf of NCD Global Health Research Group of Association of Pacific Rim Universities, worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel) 2022;14:2230. https://doi.org/10.3390/cancers14092230.Search in Google Scholar PubMed PubMed Central

3. Raju, MV, Chandrasekaran, MK, Rajendran, MS, Kanniappan, GV, Ahalliya, RM, Dugganaboyana, GK, et al.. Deciphering the therapeutic, larvicidal, and chemical pollutant degrading properties of leaves-mediated silver nanoparticles obtained from Alpinia purpurata. BioResources 2024;19:3328–52. https://doi.org/10.15376/biores.19.2.3328-3352.Search in Google Scholar

4. Wang, L, Lu, B, He, M, Wang, Y, Wang, Z, Du, L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 2022;10:811044. https://doi.org/10.3389/fpubh.2022.811044.Search in Google Scholar PubMed PubMed Central

5. Wilkinson, L, Gathani, T. Understanding breast cancer as a global health concern. Br J Radiol 2022;95:20211033. https://doi.org/10.1259/bjr.20211033.Search in Google Scholar PubMed PubMed Central

6. Raju, MV, Sekar, S, Chandrasekaran, MK, Rajendran, MS, Ahalliya, RM. Evaluation of the antioxidant activity of novel south Indian plant Commelina forskaolii and its prospective anticancer activity in Hep G2 cells. Indian J Nat Prod Resour 2024;15:65–72. https://doi.org/10.56042/ijnpr.v15i1.4468.Search in Google Scholar

7. Sabu, A, Selvaraj, J, Gayathridevi, R, Dilipan, E. In-vitro anticancer activity of Rauvolfia tetraphylla extract on MCF-7 breast cancer cell lines. Bioinformation 2023;19:43–7. https://doi.org/10.6026/97320630019043.Search in Google Scholar PubMed PubMed Central

8. Assefa, T, Tesso, H, Ramachandran, VP, Guta, L, Demissie, TB, Ombito, JO, et al.. In silico molecular docking analysis, cytotoxicity, and antibacterial activities of constituents of fruits of Cucumis dipsaceus. ACS Omega 2023;9:1945–55. https://doi.org/10.1021/acsomega.3c08866.Search in Google Scholar PubMed PubMed Central

9. Poornima, K, Krishnan, R, Aswathi, KV, Gopalakrishnan, VK. Toxicological evaluation of ethanolic extract of Tabernaemontana coronaria (L) R. Br. Asian Pacific J Tropical Dis 2012;2:S679–84. https://doi.org/10.1016/s2222-1808(12)60243-6.Search in Google Scholar

10. Poornima, K, Gopalakrishnan, VK. Anticancer activity of Tabernaemontana coronaria against carcinogen induced clear cell renal cell carcinoma. Chinese J Biol 2014;2014:1–8. https://doi.org/10.1155/2014/584074.Search in Google Scholar

11. Sowmya, S, Gopalakrishnan, VK, Poornima, K. Enzymatic and non-enzymatic antioxidant activity of Tabernaemontana divaricata R.Br. Against DEN and Fe-NTA induced renal damage in Wistar Albino Rats. J. Appl. Pharm. Sci. 2015;5:033–7. https://doi.org/10.7324/japs.2015.50506.Search in Google Scholar

12. Iwaloye, O, Ottu, PO, Olawale, F, Babalola, OO, Elekofehinti, OO, Kikiowo, B, et al.. Computer-aided drug design in anti-cancer drug discovery: what have we learnt and what is the way forward? Inform Med Unlocked 2023;41:101332. https://doi.org/10.1016/j.imu.2023.101332.Search in Google Scholar

13. Luongo, F, Colonna, F, Calapà, F, Vitale, S, Fiori, ME, De Maria, R. PTEN tumor-suppressor: the dam of stemness in cancer. Cancers (Basel) 2019;11:1076. https://doi.org/10.3390/cancers11081076.Search in Google Scholar PubMed PubMed Central

14. Fujita, K, Nonomura, N. Role of androgen receptor in prostate cancer: a review. World J Mens Health 2019;37:288–95. https://doi.org/10.5534/wjmh.180040.Search in Google Scholar PubMed PubMed Central

15. Shi, Y, Riese, DJ, Shen, J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol 2020;11:574667. https://doi.org/10.3389/fphar.2020.574667.Search in Google Scholar PubMed PubMed Central

16. Swain, SM, Shastry, M, Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023;22:101–26. https://doi.org/10.1038/s41573-022-00579-0.Search in Google Scholar PubMed PubMed Central

17. Massacci, G, Perfetto, L, Sacco, F. The Cyclin-dependent kinase 1: more than a cell cycle regulator. Br J Cancer 2023;129:1707–16. https://doi.org/10.1038/s41416-023-02468-8.Search in Google Scholar PubMed PubMed Central

18. Kalkan, BM, Baykal, AT, Cicek, E, Acilan, C. Comprehensive proteomics analysis reveals novel NEK2-Regulated pathways and therapeutic targets in cancer. Biochem Biophys Res Commun 2024;734:150779. https://doi.org/10.1016/j.bbrc.2024.150779.Search in Google Scholar PubMed

19. Surekha, K, Nachiappan, M, Prabhu, D, Choubey, SK, Biswal, J, Jeyakanthan, J. Identification of potential inhibitors for oncogenic target of dihydroorotate dehydrogenase using in silico approaches. J Mol Struct 2017;1127:675–88. https://doi.org/10.1016/j.molstruc.2016.08.015.Search in Google Scholar

20. Prabhu, D, Rajamanikandan, S, Saritha, P, Jeyakanthan, J. Evolutionary significance and functional characterization of streptomycin adenylyl transferase from Serratia marcescens. J Biomol Struct Dyn 2019;38:4418–31. https://doi.org/10.1080/07391102.2019.1682046.Search in Google Scholar PubMed

21. Mohan, A, Rendine, N, Mohammed, MKS, Jeeva, A, Ji, HF, Talluri, VR. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 Mpro. Mol Divers 2022;26:1645–61. https://doi.org/10.1007/s11030-021-10298-0.Search in Google Scholar PubMed PubMed Central

22. Dhamodiran, M, Chinnaperumal, K, Danish, J, Venkatesan, G, Alshiekheid, MA, Suseem, SR. Isolation, structural elucidation of bioactive compounds and their wound-healing ability, antibacterial and in silico molecular docking applications. Environ Res 2024;252:119023. https://doi.org/10.1016/j.envres.2024.119023.Search in Google Scholar PubMed

23. Kaliaperumal, K, Salendra, L, Liu, Y, Ju, Z, Sahu, SK, Elumalai, S, et al.. Isolation of anticancer bioactive secondary metabolites from the sponge-derived endophytic fungi Penicillium sp. and in-silico computational docking approach. Front Microbiol 2023;14:1216928. https://doi.org/10.3389/fmicb.2023.1216928.Search in Google Scholar PubMed PubMed Central

Received: 2024-12-09

Accepted: 2025-02-28

Published Online: 2025-03-28

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jcim-2024-0443

Keywords for this article

Tabernaemontana coronaria; Jerantinine A; molecular docking; prostate cancer; breast cancer; ovarian cancer